KIRKLAND, Washington, March 9 /PRNewswire/ --
ProteoTech Inc. announced today that both Dr. Alan D. Snow, Chairman, President CSO, and Dr. Luke Esposito, Director of In Vitro Screening, will present at the 9th International Conference for Alzheimer's and Parkinson's Diseases, to be held in Prague, Czech Republic, March 11-15, 2009. On Sunday March 15, Dr. Alan D. Snow will give an oral presentation discussing promising results pertaining to ProteoTech's current Phase 1A human clinical trial with the small molecule Exebryl-1(R) for the treatment of mild-to-moderate Alzheimer's disease. Dr. Snow's talk is entitled: Exebryl-1(R): A Novel Small Molecule Currently in Human Clinical Trials as a Disease-Modifying Drug for the Treatment of Alzheimer's Disease.
(Logo: http://www.newscom.com/cgi-bin/prnh/20090226/SF76109LOGO)
Dr. Luke Esposito on Saturday March 14-Sunday March 15 will present during the Synucleinopathies poster session. Dr. Esposito's presentation is entitled: Synuclere(TM): Development of a Novel Small Molecule that Effectively Reduces Alpha-Synuclein Aggregation and Improves Motor Dysfunction. Synuclere(TM) is a novel small molecule developed by ProteoTech that looks promising as a future disease-modifying treatment for Parkinson's disease and related disorders. ProteoTech's work in Parkinson's disease was partially funded by a LEAPS award from The Michael J. Fox Foundation for Parkinson's Research.
About ProteoTech: ProteoTech is a private drug development Company founded in 1996 that is a world-leader in therapeutics targeting amyloid diseases. With over 175 patents in its intellectual property estate, ProteoTech is in human clinical trials for its orally active small molecule drug Exebryl-1(R) for the treatment of mild-to-moderate Alzheimer's disease. The Company is in late-stage pre-clinical development with Synuclere(TM) for the treatment of Parkinson's disease, and Systebryl(TM) for the treatment of Systemic Amyloidosis. ProteoTech is also in late stage pre-clinical development for a novel small peptide called PeptiClere(TM) as a nasal spray for the treatment of Alzheimer's disease. Lastly, ProteoTech is developing a novel small molecule compound for the treatment of amyloidosis associated with type 2 diabetes. For further information, please visit the Company's website at www.proteotech.com or contact us at info@proteotech.com.
ProteoTech Inc., +1-425-823-0400, info@proteotech.com / PHOTO: http://www.newscom.com/cgi-bin/prnh/20090226/SF76109LOGO
Comments